Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | PHASE1 | COMPLETED | 164 | — | — | Jun 29, 2016 | Jun 27, 2024 | Sep 27, 2024 | 14 | United States, Belgium +5 |
| Arm | Type | Description |
|---|---|---|
| LY3300054 | EXPERIMENTAL | LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle. |
| LY3300054 + Ramucirumab | EXPERIMENTAL | LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle. |
| Abemaciclib + LY3300054 | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + Abemaciclib (Concurrent Dosing) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + Abemaciclib | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required. |
| LY3300054 + Merestinib | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle. |
| LY3300054 Expansion (Metastatic Cutaneous Melanoma) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 Expansion (MSI-H Solid Tumors) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 of a 28 day cycle. |
| : LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H) | EXPERIMENTAL | LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 + LY3321367 Expansion | EXPERIMENTAL | LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 + Merestinib (Pancreatic Cancer) Expansion | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle. |
| Name | Type | Description |
|---|---|---|
| LY3300054 | DRUG | Administered IV |
| Ramucirumab | DRUG | Administered IV |
| Abemaciclib | DRUG | Administered orally |
| Merestinib | DRUG | Administered orally |
| LY3321367 | DRUG | Administered IV |
Inclusion Criteria: * Histologic or cytologic confirmation of advanced solid tumor. * For LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin. * For LY3...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |